|
IATDMCT Monthly eNews
September 2026
| | |
FEATURED IN THIS ISSUE:
››› Meet the Council Members!
››› Follow IATDMCT Institutional LinkedIn, X(Twitter), and Instagram for Updates
››› IATDMCT Podcast: Eight Drugs a Week
››› IATDMCT Congress 2026 – Rennes, France
››› Published Ahead-of-Print in Therapeutic Drug Monitoring – Latest Update
››› IATDMCT Events Calendar
››› Contact E-News
| | |
Bin Lin
Councilor of IATDMCT
| | |
Bridging Practice and Innovation: My Journey with TDM and Clinical Toxicology
As a Councillor of IATDMCT and Vice Chair of the Regional Asia Pacific Section (RAPS), I am currently serving at the intersection of clinical pharmacy, therapeutic drug monitoring, and hospital management to advance patient care at the grassroots level.
I serve as Director of the Pharmacy Department at Changxing People's Hospital in Zhejiang Province, China. I am also Executive Director of the Huzhou Key Laboratory of Intelligent Pharmacy and Individualized Therapy, and an A/Professor in Evidence Based Medicine at Huzhou Normal University. My journey in TDM and clinical pharmacy began with specialized training as a clinical pharmacist in anti-infective therapy, and over the years I have built a career centered on bringing precision dosing and advanced analytical services to a primary hospital setting.
My IATDMCT journey
My relationship with IATDMCT began when I recognized the need to connect our frontline practice with the global scientific community. What started as a desire to learn from international experts soon became something much more meaningful. IATDMCT has become a professional home—a community that continually challenges and inspires me to grow both scientifically and professionally.
In 2024, I had the privilege of becoming a founding member of IATDMCT-RAPS, serving as the only representative from mainland China on the inaugural 12-member committee. This was a much-awaited development designed to strengthen engagement, collaboration, and education across the Asia-Pacific region. Since then, it has been incredibly rewarding to help shape the Section's mission and to co-moderate our webinar series, bringing together colleagues from Singapore, India, Bhutan, Oman, and beyond to share frontline experience in TDM guideline implementation, monoclonal antibody monitoring, and antimicrobial stewardship. These experiences have reinforced my belief in the value of building connections that allow knowledge, experience, and best practices to flow across regions.
My work and research
At Changxing People's Hospital, I have focused on demonstrating that high-quality TDM and clinical toxicology need not be confined to large academic centers. Under my leadership, the pharmacy department has established a regional TDM center, developed more than fifty TDM assays using LC-MS/MS.
My research focuses on the personalized use of anti-infective agents in critically ill patients, particularly dose optimization during extracorporeal membrane oxygenation (ECMO) support. My team and I have developed and validated sensitive UPLC-MS/MS methods for simultaneous quantification of antiviral and antibiotic agents, including nirmatrelvir/ritonavir and linezolid. Our work on population pharmacokinetic modeling of linezolid in postoperative neurosurgical patients—presented as an oral communication at the 2025 Regional Asia-Pacific TDM Congress in Penang—provided a new paradigm for individualized dosing in central nervous system infections. I also had the privilege of leading the development of an expert consensus on linezolid TDM and individualized dosing, published in Frontiers in Public Health.
A message to our members
To my fellow members, I would like to express my sincere gratitude for your continued engagement and contributions. TDM and clinical toxicology are not merely laboratory services—they are bridges between science and the bedside. Whether you are working in a large academic center or a primary hospital, our shared responsibility is to turn concentration data into better decisions for the patient in front of us.
I encourage all members, especially young pharmacists and scientists from underrepresented regions, to remain actively involved, seek opportunities to contribute, and share your frontline stories. IATDMCT thrives through the collective contributions of its members, and each of us has an important role to play. I would also encourage you to serve as ambassadors for IATDMCT by inspiring colleagues and trainees to become part of our community. Membership growth is not simply about increasing numbers; it is about expanding our collective expertise, strengthening our global voice, and creating new opportunities for collaboration, learning, and innovation.
Together, we can continue advancing the science and practice of therapeutic drug monitoring and clinical toxicology, ensuring that IATDMCT remains a vibrant and influential international community for years to come.
| | |
Follow IATDMCT Institutional LinkedIn, X(Twitter), and Instagram for updates
Find the latest news and follow our IATDMCT institutional page on LinkedIn, X(Twitter) @IATDMCT or Instagram!
| | |
IATDMCT Podcast: Eight Drugs a Week Episode 20 – Lucy in the Sky with Diamonds: Keeping up with New Psychoactive Substances
For this episode we will take a slightly different trip - one that takes us into the rapidly changing world of new psychoactive drugs. From synthetic cannabinoids and novel stimulants, to designer benzodiazepines and emerging psychedelics, the landscape is constantly evolving. New molecules appear faster than we can sometimes characterise them, creating major challenges for clinicians, toxicologists, laboratories and regulators. So, how can we detect these entities when we may not even know what we are looking for? And what can pharmacology and toxicology tell us about their clinical effects and their risks?
In this episode, we are joined by Souleiman El Balkhi and Richard Kevin, who walk us through what it takes to make sense of the vast NPS terrain.
| | |
Save the Dates!
IATDMCT Congress 2026 – Rennes, France, September 27 – 30
Precision medicine: moving from legend to reality
The Rennes pharmacology team is delighted to welcome you to the joint congress of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and the French Society of Pharmacology and Therapeutics (SFPT). These two eminent learning societies are joining forces for the first time in France to foster knowledge in precision medicine and promote research on drugs.
During four days, Rennes will be the capital of pharmacology, therapeutics, and clinical toxicology. In the heart of the city, the Couvent des Jacobins. Formerly a religious site, then a educational place and finally a military centre, it now plays a central role in the sharing of culture and knowledge. While retaining its historical roots, this site is now firmly focused on the future!
It is in keeping with this spirit that we will meet next September. Bringing together pharmacologists, toxicologists and clinicians with their expertise in medical drugs, we will turn the attractive promise of precision medicine into a clinical reality.
We are very excited to share all this knowledge and look forward to seeing many of you in Rennes!
Please, disseminate the unique scientific event within your professional and scientific networks!
| | Published Ahead-Of-Print in Therapeutic Drug Monitoring – Latest Update | | |
Stay ahead with the latest scientific research developments in the fields of TDM and CT!
The monthly Therapeutic Drug Monitoring column provides you with the latest posts of ahead-of-print. Bringing to you articles posted online July 28 – Aug 14, 2026:
REVIEW ARTICLE:
Exploring the Clinical Pharmacokinetics of Sitagliptin in Healthy and Diseased Populations: A Systematic Critical Review
Tahir Saleem, Muhammad Fawad Rasool, Hamid Saeed, Faleh Alqahtani
August 14, 2026
ORIGINAL ARTICLES:
KCNA3 Gene Polymorphism Affects the Efficacy and Plasma Concentration of Perampanel in Patients With Refractory Epilepsy
Ting Zhao, Hong-Jian Li, Hui-Lan Zhang, Jing Yu, Yan Sun, Lu-Hai Yu, Lu-Feng Cheng
August 13, 2026
Early Tacrolimus Underexposure Predicts Acute Rejection After Renal Transplantation
Amélie F. Menke, Camille Antony, Lino Henkel, Göran R. Boeckel, Philipp Houben, Felix Becker, Hermann Pavenstädt, Ulrich Jehn, Stefan Reuter
August 12, 2026
Optimizing Immunosuppressant Transition Strategies: Population Pharmacokinetic Analysis of Tacrolimus to Sirolimus Conversion in Renal Transplantation
Jessica Gadsby, Amy Page, Dipesh Patel, Damini Amin, Jorge Jesus-Silva, Hussain Mulla
August 6, 2026
Apparent Elevation of Whole-Blood Tacrolimus Concentrations Following High-Dose Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients
Takashi Tsujimoto, Hajime Sasaki, Toyoshi Seito, Hiroki Kanou, Asuka Yamamoto, Tatsu Tanabe
July 28, 2026
A Retrospective Analysis of Itraconazole and Hydroxy-Itraconazole Serum Concentrations Correlation to Clinical Outcomes of Histoplasmosis Treatment
Danielle Firkus, Ryan W. Stevens, Omar M. Abu Saleh, Kristin Cole, Mark J. Enzler, Meghan Haan, Joseph Herges, Paul J. Jannetto, Paschalis Vergidis, Christina G. Rivera
July 28, 2026
Short Communication:
High-throughput UHPLC-MS/MS Assay for the Quantification of Venetoclax in Patients with Acute Myeloid Leukemia and Assessment of Clinical Application: A Short Communication
Yuri Hatano, Ken Shiraiwa, Ryota Tanaka, Yoshio Sueshige, Yuko Murakami, Hironori Abe, Ryosuke Tatsuta, Kazuki Okuhiro, Kuniko Takano, Masao Ogata, Hiroki Itoh
July 31, 2026
LETTER TO THE EDITOR:
Broad-Spectrum Drug Screening Positivity Rates: Interpreting the Findings
Ayla Yildiz
August 14, 2026
››Submit your high quality research – Information for authors.
| Visit the Therapeutic Drug Monitoring (TDM) Website to read your Articles of Interest...
| | |
4:30 PM - 6:00 PM (India Time)
HOST INSTITUTE
Amrita Institute of Medical Sciences (AIMS), Kochi, India
CHAIR
Dr. Smita Pattanaik
Professor, Clinical Pharmacology Unit
Post Graduate Institute of Medical Education and Research, Chandigarh, India
Dr. Paula Keating
Ph.D. and FFSc (RCPA)
Scientific Officer
Canterbury Health Laboratory, Christchurch, New Zealand
MODERATORS
Dr Vishnu Eriyat
Assistant Professor,
Clinical Pharmacology Unit, Christian Medical College, Vellore
Dr Niveditha K
Assistant Professor,
Clinical Pharmacology Division, KMC Manipal
PROGRAM
Welcome and review of the agenda
Dr. Smita Pattanaik
Guest Lecture: “TDM of Monoclonal Antibodies: HPLC-Based Assays for Drug Levels and Anti-Drug Antibodies”
Dr. Paula Keating
Introduction to the Host Institution
Dr. Princy Palatty
Head, Department of Pharmacology
Amrita Institute of Medical Sciences (AIMS), Kochi
Dr Laxmi Govindraj
Associate Professor
Amrita Institute of Medical Sciences (AIMS), Kochi
Presentation: Therapeutic drug monitoring of sorafenib and lenvatinib in hepatocellular carcinoma patients
Ms. Merin
Research scholar
Amrita Institute of Medical Sciences (AIMS), Kochi
Presentation: Effectiveness, safety and quality of life of cancer patients on regorafenib therapy
Dr Febina MB
Senior resident
Amrita Institute of Medical Sciences (AIMS), Kochi
| | |
PROGRAM
8:30 hrs – Registration & welcome coffee
9:00 hrs – Introduction
Session 1: Updates from new studies: TDM in clinical practice
9:10 hrs – Updates from two randomized controlled studies TODORA and ADDORA using TDM in clinical practice in patients with rheumatic diseases
Drs. Sadaf Atiqi, Reade, the Netherlands
9:30 hrs – TDM in IBD: Insights from Prospective Clinical Trials
Dr. Mark Löwenberg MD, AmsterdamUMC, the Netherlands
9:50 hrs – TDM updates in dermatology
Dr. Teresa Tsakok, King’s College London, United Kingdom
10:10 hrs – Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A
Dr Corien Eckhardt, UMC Utrecht, the Netherlands
10:30 hrs – pdates from the SUPERNEXT study: personalised extended interval dosing of natalizumab in patients with multiple sclerosis
Drs Liza Gelissen, Amsterdam UMC, the Netherlands
10:50 hrs – Panel discussion
11.00 hrs – Coffee break
Session 2: Developments in PK modelling in TDM
11:30 hrs – Model-informed precision dosing in TDM of biologics
Drs Stefan van den Berg, Sanquin, the Netherlands
11:50 hrs – Using artificial intelligence in TDM models
Drs Alexander Janssen, Amsterdam UMC, the Netherlands
12:10 hrs – Clinical pharmacology of infliximab in pediatrics
Dr Tim Preijers, Erasmus MC, the Netherlands
12:30 hrs – Panel discussion
12:45 hrs – Lunch
Session 3: Implementation of TDM in clinical practice
13:45 hrs – Patient perspective in TDM of biologics
Drs Suzanne Anjie, AmsterdamUMC, the Netherlands and Drs Maureen Leeuw, Reade, the Netherlands
14:00 hrs – How to implement home-monitoring
TBC
14:15 hrs – Implementation of home-monitoring of biologics in neurology
Dr. Zoé van Kempen, Amsterdam UMC, the Netherlands
14:30 hrs – Panel discussion
14:45 hrs – Coffee break
Session 4: Future of TDM
15:15 hrs – Update and future of TDM of biologics from Norway
Prof. Dr. Espen A Haavardsholm, University of Oslo/Diakonhjemmet Hospital, Norway
15:45 hrs – The future of TDM of biologics in different fields
5 minutes pitches followed by panel discussion
Overview Gastrointestinal field
Dr Mark Löwenberg, AmsterdamUMC, the Netherlands
Overview Rheumatology field
Prof. Dr. Gerg-Jan Wolbink
Overview Dermatology field
Dr. Teresa Tsakok, King’s College London, United Kingdom
Overview Neurology field
Prof. Dr. Joep Killestein, AmsterdamUMC, the Netherlands
Overview Oncology field
Dr. Dirk-Jan Moes, LUMC, the Netherlands
16:45 hrs – FAREWELL DRINKS and network reception
| |
Regional Asia-Pacific Section (RAPS) Conference, June 18-20, 2027
| | |
Communications Committee
Advisor: Manuela Neuman
Co-editor: Ryuji Kato
Co-editor: Yoko Urashima
NOTE: Items appearing in the IATDMCT monthly E-News do not necessarily have the endorsement of the Association.
| Email your Hot Topic to IATDMCT Monthly E-News...
| | | | |
